Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Hsin-Fu LeeYi-Hsin ChanChi ChuangPei-Ru LiYung-Hsin YehFu-Chih HsiaoJian-Rong PengLai-Chu SeePublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
Our data indicated that SGLT2i, compared with DPP4i, were associated with lower risks of HFH, coronary revascularization, composite renal outcomes, and all-cause mortality for patients with T2D after PCI. Further randomized or prospective studies can investigate the effects of SGLT2i in patients with T2D after PCI.
Keyphrases
- percutaneous coronary intervention
- coronary artery disease
- lower limb
- st segment elevation myocardial infarction
- acute myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- antiplatelet therapy
- coronary artery bypass grafting
- atrial fibrillation
- double blind
- coronary artery bypass
- type diabetes
- newly diagnosed
- metabolic syndrome
- human health
- risk assessment
- adipose tissue
- left ventricular